Access cutting-edge high-grade glioma treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access high-grade glioma specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related high-grade glioma treatment provided free
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Sponsor: Rigel Pharmaceuticals
Check if you qualify for this high-grade glioma clinical trial in Washington Dc, DC
If you're searching for high-grade glioma treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced high-grade glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.